Core Viewpoint - The company, Meizhong Jiahe (02453), announced that its subsidiary, Guangzhou Taihe Oncology Hospital, has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its capabilities in oncology treatment and competitive advantage in the market [1] Group 1: Regulatory Approval - Guangzhou Taihe Oncology Hospital received approval from the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration on December 8, 2025, to be included in the designated medical institution list for the Guangdong-Hong Kong-Macao Greater Bay Area [1] - The "Hong Kong-Macao Drug and Medical Device Access" initiative is a key measure under the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [1] Group 2: Business Expansion - The qualification allows the company to import and use urgently needed drugs and advanced medical devices that have been approved in Hong Kong and Macao but not yet in mainland China [1] - This move will enable the company to introduce innovative oncology drugs and expand its business boundaries, creating a differentiated competitive advantage in the oncology market [1] Group 3: Clinical and Research Enhancement - The initiative will facilitate deeper integration with Hong Kong and Macao medical resources, improving clinical diagnosis and treatment levels as well as research capabilities [1] - By introducing cutting-edge medical devices and optimizing oncology treatment plans, the company aims to align with international medical standards and enhance the overall patient service experience and treatment outcomes [1]
美中嘉和：广州泰和肿瘤医院获批进入“港澳药械通”指定医疗机构名单